{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T01:24:11Z","timestamp":1759541051753,"version":"3.37.3"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2005,9,1]],"date-time":"2005-09-01T00:00:00Z","timestamp":1125532800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Journal of Drug Metabolism and Pharmacokinetics"],"published-print":{"date-parts":[[2005,9]]},"DOI":"10.1007\/bf03190621","type":"journal-article","created":{"date-parts":[[2010,8,7]],"date-time":"2010-08-07T10:09:59Z","timestamp":1281175799000},"page":"203-218","source":"Crossref","is-referenced-by-count":1,"title":["Single and chronic administration of ciprofibrate or of ciprofibrate-glycinate in male Fischer 344 rats: Comparison of the effects on morphological and biochemical parameters in liver and blood"],"prefix":"10.1007","volume":"30","author":[{"given":"Amelie","family":"Lupp","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elke","family":"Karge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manfred","family":"Danz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Deufel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Herbert","family":"Oelschl\u00e4ger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wolfgang","family":"Klinger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"BF03190621_CR1","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1056\/NEJM198711123172001","volume":"317","author":"M.H. Frick","year":"1987","unstructured":"Frick M.H., Elo O., Haapa K. (1987): Helsinki Heart Study: primary prevention trial with gemfibrozil in middle-aged men with dyslipidaemia: safety in treatment, changes in risk factors, and incidence of coronary heart disease. N. Engl. J. Med., 317,1237\u20131245.","journal-title":"N. Engl. J. Med."},{"key":"BF03190621_CR2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0021-9150(03)00156-4","volume":"171","author":"M.J. Chapman","year":"2003","unstructured":"Chapman M.J. (2003): Fibrates in 2003: therapeutic action in atherogenic dyslipidaemia and future perspectives. Atherosclerosis, 171,1\u201313.","journal-title":"Atherosclerosis"},{"key":"BF03190621_CR3","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1055\/s-2003-42720","volume":"Ill","author":"H.C. Geiss","year":"2003","unstructured":"Geiss H.C., Dietlein M., Parhofer K.G. (2003): Influence of etofibrate on LDL-subtype distribution in patients with diabetic dyslipoproteinemia. Exp.Clin. Endocrinol. Diab., Ill,322\u2013324.","journal-title":"Exp.Clin. Endocrinol. Diab."},{"key":"BF03190621_CR4","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.2337\/diacare.26.5.1513","volume":"26","author":"S.J. Robins","year":"2003","unstructured":"Robins S.J., Rubins H.B., Faas F.H., Schaefer E.J., Elam M.B., Anderson J.W., Collins D. (2003): Insulin resistance and cardiovascular events with low HDL cholesterol: the Veterans Affairs HDL Intervention Trial (VA-HIT). Diabetes Care, 26,1513\u20131517.","journal-title":"Diabetes Care"},{"key":"BF03190621_CR5","doi-asserted-by":"crossref","first-page":"2177","DOI":"10.2165\/00003495-200464190-00003","volume":"64","author":"J.P. Despr\u00e9s","year":"2004","unstructured":"Despr\u00e9s J.P., Lemieux I., Robins S.J. (2004): Role of fibric acid derivatives in the management of risk factors for coronary heart disease. Drugs, 64, 2177\u20132198.","journal-title":"Drugs"},{"key":"BF03190621_CR6","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1023\/B:PHAM.0000041444.06122.8d","volume":"21","author":"D.H. Raalte Van","year":"2004","unstructured":"Van Raalte D.H., Li M., Pritchard P.H., Wasan K.M. (2004): Peroxisome proliferator-activated receptor (PPAR)-\u03b1: a pharmacological target with a promising future. Pharmac. Res., 21,1531\u20131538.","journal-title":"Pharmac. Res."},{"key":"BF03190621_CR7","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S1262-3636(07)70083-6","volume":"30","author":"B. Verges","year":"2004","unstructured":"Verges B. (2004): Clinical interest of PPARs ligands. Diab. Metabol., 30,7\u201312.","journal-title":"Diab. Metabol."},{"key":"BF03190621_CR8","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.jacc.2004.10.031","volume":"45","author":"R.S. Birjmohun","year":"2005","unstructured":"Birjmohun R.S., Hutten B.A., Kastelein J.J., Stroes E.S. (2005): Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds: a meta-analysis of randomized controlled trials. J. Am. Coll. Cardiol., 45,185\u2013197.","journal-title":"J. Am. Coll. Cardiol."},{"key":"BF03190621_CR9","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1038\/283397a0","volume":"283","author":"J.K Reddy","year":"1980","unstructured":"Reddy J.K, Azarnoff D.L., Hignite C.E. (1980): Hypolipidaemic hepatic peroxisome proliferators form a novel class of chemical carcinogens. Nature, 283,397\u2013398.","journal-title":"Nature"},{"key":"BF03190621_CR10","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/0015-6264(81)90509-5","volume":"19","author":"A.J. Cohen","year":"1981","unstructured":"Cohen A.J., Grasso P. (1981): Review of the hepatic response to hypolipidaemic drugs in rodents and assessment of its toxicological significance to man. Food Cosmet. Toxicol., 19,585\u2013605.","journal-title":"Food Cosmet. Toxicol."},{"key":"BF03190621_CR11","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S0027-5107(99)00232-8","volume":"448","author":"J.C. Corton","year":"2000","unstructured":"Corton J.C., Lapinskas P.J., Gonzalez F.J. (2000): Central role of PPARalpha in the mechanism of action of hepatocarcinogenic peroxisome proliferators. Mutat. Res., 448,139\u2013151.","journal-title":"Mutat. Res."},{"key":"BF03190621_CR12","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1021\/jm990554g","volume":"43","author":"T.M. Willson","year":"2000","unstructured":"Willson T.M. (2000): The PPARs: From orphan receptors to drug discovery. J. Med. Chem. 43,527\u2013550.","journal-title":"J. Med. Chem."},{"key":"BF03190621_CR13","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.mrfmmm.2003.12.019","volume":"549","author":"P.D. Cornwell","year":"2004","unstructured":"Cornwell P.D., De Souza A.T., Ulrich R.G. (2004): Profiling of hepatic gene expression in rats treated with fibric acid analogs. Mutat. Res., 549, 131\u2013145.","journal-title":"Mutat. Res."},{"key":"BF03190621_CR14","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1042\/bst0230425","volume":"23","author":"J.W. DePierre","year":"1995","unstructured":"DePierre J.W., Sohlenius A.K., Cai Y., Eriksson A.M., Andersson K., Sundberg C. (1995): Peroxisome proliferation in response to xenobiotics. Biochem. Soc. Transact., 23,425\u2013429.","journal-title":"Biochem. Soc. Transact."},{"key":"BF03190621_CR15","doi-asserted-by":"crossref","first-page":"695","DOI":"10.3109\/00498259609046743","volume":"26","author":"M.J. Graham","year":"1996","unstructured":"Graham M.J., Winham M.A., Old S.L., Gray T.J.B. (1996): Comparative hypolipidaemic and peroxisomal effects of ciprofibrate, clofibric acid, and their respective difluorocyclopropyl and 4-fluorosubstituted analogues in rat. Xenobiotica, 26,695\u2013707.","journal-title":"Xenobiotica"},{"key":"BF03190621_CR16","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/BF03190964","volume":"22","author":"N.S. Yaacob","year":"1997","unstructured":"Yaacob N.S., Norazmi M.N., Kass G.E.N., Gibson G.G. (1997): Use of competitive RT-PCR in the molecular analysis of peroxisome proliferation. Eur. J. Drug Metab. Pharmacokin., 22,321\u2013324.","journal-title":"Eur. J. Drug Metab. Pharmacokin."},{"key":"BF03190621_CR17","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/0041-008X(89)90056-2","volume":"97","author":"M.R. Nemali","year":"1989","unstructured":"Nemali M.R., Reddy M.K., Usuda N., Reddy P.G., Comeau L.D., Rao M.S., Reddy J.K. (1989): Differential induction and regulation of peroxisomal enzymes: predictive value of peroxisome proliferation in identifying certain nonmutagenic carcinogens. Toxicol. Appl. Pharmacol., 97, 72\u201387.","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"BF03190621_CR18","first-page":"171","volume":"114","author":"J.K. Reddy","year":"1984","unstructured":"Reddy J.K., Lalwani N.D., Qureshi S.A., Reddy M.K., Moehle CM. (1984): Induction of hepatic peroxisome proliferation in non-rodent species, including primates. Am. J. Pathol., 114,171\u2013183.","journal-title":"Am. J. Pathol."},{"key":"BF03190621_CR19","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1007\/BF02034935","volume":"65","author":"J.M. Makowska","year":"1991","unstructured":"Makowska J.M., Bonner F.W., Gibson G.G. (1991): Comparative induction of cytochrome P450IVA1 and peroxisome proliferation by ciprofibrate in the rat and marmoset. Arch. Toxicol., 65,106\u2013113.","journal-title":"Arch. Toxicol."},{"key":"BF03190621_CR20","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1002\/jbt.2570070308","volume":"7","author":"J.M. Makowska","year":"1992","unstructured":"Makowska J.M., Gibson G.G., Bonner F.W. (1992): Species differences in ciprofibrate induction of hepatic cytochrome P450 4A1 and peroxisome proliferation. J. Biochem. Toxicol., 7,183\u2013191.","journal-title":"J. Biochem. Toxicol."},{"key":"BF03190621_CR21","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1006\/faat.1994.1008","volume":"22","author":"M.J. Graham","year":"1994","unstructured":"Graham M.J., Wilson S.A., Winham M.A., Spencer A.J., Rees J.A., Old S.L., Bonner F.W. (1994): Lack of peroxisome proliferation in marmoset liver following treatment with ciprofibrate for three years. Fundam. Appl. Toxicol., 22,58\u201364.","journal-title":"Fundam. Appl. Toxicol."},{"key":"BF03190621_CR22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1677\/jme.0.0220001","volume":"22","author":"P.R. Holden","year":"1999","unstructured":"Holden P.R., Tugwood J.D. (1999): Peroxisome proliferator-activated receptor alpha: role in rodent liver cancer and species differences. J. Mol. Endocrinol., 22,1\u20138.","journal-title":"J. Mol. Endocrinol."},{"key":"BF03190621_CR23","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S0027-5107(99)00238-9","volume":"448","author":"B.G. Lake","year":"2000","unstructured":"Lake B.G., Rumsby P.C., Price R.J., Cunninghame M.E. (2000): Species differences in hepatic peroxisome proliferation, cell replication and transforming growth factor-b 1 gene expression in the rat, Syrian hamster and guinea pig. Mutat. Res., 448,213\u2013225.","journal-title":"Mutat. Res."},{"key":"BF03190621_CR24","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1124\/mol.58.1.185","volume":"58","author":"C Rodriguez","year":"2000","unstructured":"Rodriguez C, Noe V., Cabrero A., Ciudad C.J., Laguna J.C (2000): Differences in the formation of PPARalpha-RXR \/ acoPPRE complexes between responsive and nonresponsive species upon fibrate administration. Mol. Pharmacol., 58,185\u2013193.","journal-title":"Mol. Pharmacol."},{"key":"BF03190621_CR25","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1093\/toxsci\/kfh071","volume":"78","author":"M. Ammerschlaeger","year":"2004","unstructured":"Ammerschlaeger M., Beigel J., Klein K.U., Mueller S.O. (2004): Characterization of the species-specificity of peroxisome proliferators in rat and human hepatocytes. Toxicol. Sei., 78,229\u2013240.","journal-title":"Toxicol. Sei."},{"key":"BF03190621_CR26","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/0306-3623(89)90187-0","volume":"20","author":"A.F. Boiteux-Antoine","year":"1989","unstructured":"Boiteux-Antoine A.F., Magdalou J., Foumel-Gigleux S., Siest G. (1989): Comparative induction of drug-metabolizing enzymes by hypolipidaemic compounds. Gen. Pharmac, 20,407\u2013412.","journal-title":"Gen. Pharmac"},{"key":"BF03190621_CR27","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/0076-6879(91)06105-C","volume":"206","author":"G.G. Gibson","year":"1991","unstructured":"Gibson G.G., Lake B.G. (1991): Induction protocols forthe cytochrome P450IVA subfamily in animals and primary hepatocyte cultures. Meth. Enzymol., 206,353\u2013363.","journal-title":"Meth. Enzymol."},{"key":"BF03190621_CR28","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/0006-2952(90)90497-9","volume":"40","author":"J.M. Makowska","year":"1990","unstructured":"Makowska J.M., Anders C, Goldfarb P.S., Bonner F., Gibson G.G. (1990): Characterization of the hepatic responses to the short-term administration of ciprofibrate in several rat strains. Co-induction of microsomal cytochrome P-450IVA1 and peroxisome proliferation. Biochem. Pharmacol., 40,1083\u20131093.","journal-title":"Biochem. Pharmacol."},{"key":"BF03190621_CR29","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/S0090-9556(25)06643-7","volume":"23","author":"R.C Zangar","year":"1995","unstructured":"Zangar R.C, Woodcroft K.J., Kocarek T.A., Novak R.F. (1995): Xenobiotic-enhanced expression of cytochrome P450 2E and 2B1\/2B2 in primary cultured rat hepatocytes. Drug Metab. Dispos., 23,681\u2013687.","journal-title":"Drug Metab. Dispos."},{"key":"BF03190621_CR30","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/S0041-008X(96)80015-9","volume":"141","author":"R.C Zangar","year":"1996","unstructured":"Zangar R.C, Woodcroft K.J., Novak R.F. (1996): Differential effects of ciprofibrate on renal and hepatic cytochrome P450 2E1 expression. Toxicol. Appl. Pharmacol., 141,110\u2013116.","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"BF03190621_CR31","doi-asserted-by":"crossref","first-page":"297","DOI":"10.3109\/00498259609046709","volume":"26","author":"B.G. Lake","year":"1996","unstructured":"Lake B.G., Charzat C, Tredger J.M., Renwick A.B., Beamand J.A., Price R.J. (1996): Induction of cytochrome P450 isoenzymes in cultured precision-cut rat and human liver slices. Xenobiotica, 26,297\u2013306.","journal-title":"Xenobiotica"},{"key":"BF03190621_CR32","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/0163-7258(94)90043-4","volume":"63","author":"A. Lozada","year":"1994","unstructured":"Lozada A., Dujovne C.A. (1994): Drug interactions with fibric acids. Pharmacol. Ther., 63,163\u2013176.","journal-title":"Pharmacol. Ther."},{"key":"BF03190621_CR33","doi-asserted-by":"crossref","first-page":"355","DOI":"10.2165\/00002018-199819050-00003","volume":"19","author":"H.E. Bays","year":"1998","unstructured":"Bays H.E., Dujovne C.A. (1998): Drug interactions of lipid-altering drugs. Drug Safety, 19,355\u2013371.","journal-title":"Drug Safety"},{"key":"BF03190621_CR34","doi-asserted-by":"crossref","first-page":"155","DOI":"10.2165\/00003088-199834020-00003","volume":"34","author":"D.B. Miller","year":"1998","unstructured":"Miller D.B., Spence J.D. (1998): Clinical pharmacokinetics of fibric acid derivatives (fibrates). Clin. Pharmacokinet., 34,155\u2013162.","journal-title":"Clin. Pharmacokinet."},{"key":"BF03190621_CR35","first-page":"607","volume-title":"Cytochrome P450: structure, mechanism and biochemistry","author":"M.A. Correia","year":"1995","unstructured":"Correia M.A. (1995): Rat andhuman liver cytochrome P450: substrate and inhibitor specificities and functional markers. In: Ortiz de Montellano P.R. (ed.). Cytochrome P450: structure, mechanism and biochemistry. Plenum Press, New York and London, 2nd edition, 607\u2013630.","edition":"2nd edition"},{"key":"BF03190621_CR36","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/S0090-9556(25)07113-2","volume":"19","author":"R.M. Smolowitz","year":"1991","unstructured":"Smolowitz R.M., Hahn M.E., Stegeman J.J. (1991): Immunohistochemical localization of cytochrome P-450IA1 induced by 3,3\u2032,4,4\u2032-tetrachlorobiphenyl and by 2,3,7,8-tetrachlorodibenzofuran in liver and extrahepatic tissues of the teleost Stenotomus chrysops (scup). Drug Metab. Dispos., 19,113\u2013123.","journal-title":"Drug Metab. Dispos."},{"key":"BF03190621_CR37","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0300-483X(01)00333-X","volume":"161","author":"A. Lupp","year":"2001","unstructured":"Lupp A., Danz M., M\u00fcller D. (2001): Morphology and cytochrome P450 isoforms expression in precision-cut rat liver slices. Toxicology, 161, 53\u201366.","journal-title":"Toxicology"},{"key":"BF03190621_CR38","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/0009-3084(87)90071-5","volume":"45","author":"K. Yagi","year":"1987","unstructured":"Yagi K. (1987): Lipid peroxides andhuman diseases. Chem. Phys. Lipids, 45,337\u2013351.","journal-title":"Chem. Phys. Lipids"},{"key":"BF03190621_CR39","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/0003-9861(59)90090-6","volume":"82","author":"G.L. Ellman","year":"1959","unstructured":"Ellman G.L. (1959): Tissue sulfhydryl groups. Arch. Biochem. Biophys., 82,70\u201377.","journal-title":"Arch. Biochem. Biophys."},{"key":"BF03190621_CR40","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/0003-2697(76)90326-2","volume":"74","author":"P.J. Hissin","year":"1976","unstructured":"Hissin P.J., Hilf R. (1976): A fluorometric method for determination of oxidized and reduced glutathione in tissues. Anal. Biochem., 74,214\u2013226.","journal-title":"Anal. Biochem."},{"key":"BF03190621_CR41","first-page":"146","volume":"16","author":"W. Klinger","year":"1974","unstructured":"Klinger W., M\u00fcller D. (1974): The influence of age on the protein concentration in serum, liver, and kidney of rats determined by various methods. Z. Versuchstiere, 16,146\u2013153.","journal-title":"Z. Versuchstiere"},{"key":"BF03190621_CR42","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1254\/jjp.33.1065","volume":"33","author":"T. Matsubara","year":"1983","unstructured":"Matsubara T., Otsubo S., Yoshihara E. (1983): Liver microsomal cytochrome P450-dependent O-dealkylation reaction in various animals. Jpn. J. Pharmacol., 33,1065\u20131075.","journal-title":"Jpn. J. Pharmacol."},{"key":"BF03190621_CR43","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/0003-2697(80)90505-9","volume":"107","author":"R.J. Pohl","year":"1980","unstructured":"Pohl R.J., Fouts J.R. (1980): A rapid method for assaying the metabolism of 7-ethoxyresorufin by microsomal subcellular fractions. Anal. Biochem., 107,150\u2013155.","journal-title":"Anal. Biochem."},{"key":"BF03190621_CR44","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/0003-9861(85)90138-9","volume":"238","author":"R.A. Lubet","year":"1985","unstructured":"Lubet R.A., Mayer R.T., Cameron J.W., Nims R.W., Burke M.D., Wolff T., Guengerich F.P. (1985): Dealkylation of pentoxyresorufin: arapid and sensitive assay for measuring induction of cytochrome(s) P-450 by phenobarbital and other xenobiotics in rat. Arch. Biochem. Biophys., 238,43\u201348.","journal-title":"Arch. Biochem. Biophys."},{"key":"BF03190621_CR45","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/0003-2697(78)90245-2","volume":"85","author":"A. Aitio","year":"1978","unstructured":"Aitio A. (1978): A simple and sensitive assay of 7-ethoxycoumarin deethylation. Anal. Biochem., 85,488\u2013491.","journal-title":"Anal. Biochem."},{"key":"BF03190621_CR46","unstructured":"Chang T.K.H., Crespi C.L., Waxman D.J. (1997): Spectrophotometric analysis of human CYP2E 1-catalyzed p-nitrophenol hydroxylation. In: Phillips I.R., Shephard E.A. (eds.). Methods in molecular biology, Vol. 107: Cytochrome P450 protocols, 147-152."},{"key":"BF03190621_CR47","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1042\/bj0550416","volume":"55","author":"T. Nash","year":"1953","unstructured":"Nash T. (1953): The colorimetric estimation of formaldehyde by means of the Hantzsch reaction. Biochem. J., 55,416\u2013421.","journal-title":"Biochem. J."},{"key":"BF03190621_CR48","first-page":"1149","volume":"36","author":"W. Klinger","year":"1977","unstructured":"Klinger W., MUller D. (1977): Ethylmorphine N-demethylation by liver homogenate of newborn and adult rats; enzyme kinetics and age course of Vmax and Km. Acta Biol. Med. Germ., 36,1149\u20131159.","journal-title":"Acta Biol. Med. Germ."},{"key":"BF03190621_CR49","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/0378-4347(91)80089-U","volume":"564","author":"H.A.A.M. Dirven","year":"1991","unstructured":"Dirven H.A.A.M., De Bruijn A.A.G.M., Sessink P.J.M., Jongeneelen F.J. (1991): Determination of the cytochrome P-450 IV marker, hydroxylauric acid, by high-performance liquid chromatography and fluorimetric detection. J. Chromatogr., 564,266\u2013271.","journal-title":"J. Chromatogr."},{"key":"BF03190621_CR50","first-page":"231","volume":"103","author":"N. Silman","year":"1965","unstructured":"Silman N., Artman M., Engelberg H. (1965): Effect of magnesium and spermine on the aggregation of bacterial and mammalian ribosomes. Biochem. Biophys. Acta, 103,231\u2013240.","journal-title":"Biochem. Biophys. Acta"},{"key":"BF03190621_CR51","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/S0076-6879(78)52032-6","volume":"52","author":"J.K A. Buege","year":"1978","unstructured":"Buege J.K A., Aust S.D. (1978): Microsomal lipid peroxidation. Methods Enzymol., 52,302\u2013310.","journal-title":"Methods Enzymol."},{"key":"BF03190621_CR52","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/S0076-6879(78)52037-5","volume":"52","author":"A.G. Hildebrandt","year":"1978","unstructured":"Hildebrandt A.G., Roots I., Tjoe M. (1978): Hydrogen peroxide in hepatic microsomes. Meth. Enzymol., 52,342\u2013350.","journal-title":"Meth. Enzymol."},{"key":"BF03190621_CR53","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1016\/0006-2952(87)90423-0","volume":"36","author":"R. MUller-Peddinghaus","year":"1987","unstructured":"MUller-Peddinghaus R., Wurl M. (1987): The amplified chemiluminescence test to characterize antirheumatic drugs as oxygen radical scavengers. Biochem. Pharmacol., 36,1125\u20131132.","journal-title":"Biochem. Pharmacol."},{"key":"BF03190621_CR54","first-page":"765","volume":"37","author":"M. Charmoillaux","year":"1991","unstructured":"Charmoillaux M., Goudonnet H., Mercenne F., Mounie J., Truchot R.C. (1991): Comparative and simultaneous effects of simvastatin and ciprofibrate on plasma lipid parameters and upon hepatic drug metabolizing and peroxisome proliferation marker enzymes in the male Wistarrat. Cell. Mol. Biol., 37,765\u2013771.","journal-title":"Cell. Mol. Biol."},{"key":"BF03190621_CR55","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1002\/jbt.2570070309","volume":"7","author":"I. Close","year":"1992","unstructured":"Close I., Shackleton G., Goldfarb P.S., Gibson G.G., Sharma R., Howes D. (1992): Influence of single and concurrent Clofibrate and ph\u00e9nobarbital administration on cytochrome P450-dependent mixed function oxidase activities and peroxisome proliferation in male rat liver. J. Biochem. Toxicol., 7,193\u2013198.","journal-title":"J. Biochem. Toxicol."},{"key":"BF03190621_CR56","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1177\/107424840200700404","volume":"7","author":"E. Rizos","year":"2002","unstructured":"Rizos E., Bairaktari E., Ganotakis E., Tsimihodimos V., Mikhailidis D., Elisaf M. (2002): Effect of ciprofibrate on lipoproteins, fibrinogen, renal function, and hepatic enzymes. J. Cardiovasc. Pharmacol. Then, 7,219\u2013226.","journal-title":"J. Cardiovasc. Pharmacol. Then"},{"key":"BF03190621_CR57","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0248-4900(05)80171-6","volume":"77","author":"C Pacot","year":"1993","unstructured":"Pacot C, Petit M., Caira F., Rollin M., Behechti N., Gregoire S., Cherkaoui-Malki M., Cavatz C, Moisant M., Moreau C. (1993): Response of genetically obese Zucker rats to ciprofibrate, a hypolipidemic agent, with peroxisome proliferation activity as compared to Zucker lean and Sprague-Dawley rats. Biology of the Cell, 77,27\u201335.","journal-title":"Biology of the Cell"},{"key":"BF03190621_CR58","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1053\/meta.2001.24870","volume":"50","author":"S.L. Dana","year":"2001","unstructured":"Dana S.L., Hoener P.A., Bilakovics J.M., Crombie D.L., Ogilvie K.M., Kauffman R.F., Mukherjee R., Paterniti J.R. (2001): Peroxisome proliferator-activated receptor subtype-specific regulation of hepatic and peripheral gene expression in the Zucker diabetic fatty rat. Metabolism, 50,963\u2013971.","journal-title":"Metabolism"},{"key":"BF03190621_CR59","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/0021-9150(87)90185-7","volume":"66","author":"M.P. Cleary","year":"1987","unstructured":"Cleary M.P., Kasiske B., O\u2019Donnell M.P., Keane W.F. (1987): Effect of long-term clofibric acid treatment on serum and tissue lipid and cholesterol levels in obese Zucker rats. Atherosclerosis, 66,107\u2013112.","journal-title":"Atherosclerosis"},{"key":"BF03190621_CR60","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/0021-9150(88)90186-4","volume":"74","author":"P. Olivier","year":"1988","unstructured":"Olivier P., Plancke M.O., Theret N., Marzin D., Clavey V., Fruchart J.C. (1988): Effects of fenofibrate on lipoprotein metabolism and fatty acid distribution in Zucker rats. Atherosclerosis, 74,15\u201321.","journal-title":"Atherosclerosis"},{"key":"BF03190621_CR61","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1006\/taap.1995.1171","volume":"134","author":"E.P. Gallagher","year":"1995","unstructured":"Gallagher E.P., Buetler T.M., Stapleton P.L., Wang C, Stahl D.L., Eaton D.L. (1995): The effects of diquat and ciprofibrate on mRNA expression and catalytic activities of hepatic xenobiotic metabolizing and antioxidant enzymes in rat liver. Toxicol. Appl. Pharmacol., 134,81\u201391.","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"BF03190621_CR62","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/S0041-008X(03)00231-X","volume":"191","author":"L. Richert","year":"2003","unstructured":"Richert L., Lamboley C, Viollon-Abadie C, Grass P., Hartmann N., Laurent S., Heyd B., Mantion G., Chibout S.D., Staedtler F. (2003): Effects of clofibric acid on mRNA expression profiles in primary cultures of rat, mouse and human hepatocytes. Toxicol. Appl. Pharmacol., 191, 130\u2013146.","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"BF03190621_CR63","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1007\/s00204-004-0569-9","volume":"78","author":"Z. Shaban","year":"2004","unstructured":"Shaban Z., El-Shazly S., Ishizuka M., Kimura K., Kazusaka A., Fujita S. (2004): PPARa-dependent modulation of hepatic CYP1A by clofibric acid in rats. Arch. Toxicol., 78,496\u2013507.","journal-title":"Arch. Toxicol."},{"key":"BF03190621_CR64","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s11095-004-9011-5","volume":"22","author":"T. Prueksaritanont","year":"2004","unstructured":"Prueksaritanont T., Richards K.M., Qiu Y., Strong-Basalyga K., Miller A., Li C, Eisenhandler R., Caelini E.J. (2004): Comparative effects of fibiates on drug metabolizing enzymes in human hepatocytes. Pharmacol. Res., 22,71\u201378.","journal-title":"Pharmacol. Res."}],"container-title":["European Journal of Drug Metabolism and Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF03190621.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/BF03190621\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF03190621","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,23]],"date-time":"2025-02-23T22:56:06Z","timestamp":1740351366000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/BF03190621"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,9]]},"references-count":64,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2005,9]]}},"alternative-id":["BF03190621"],"URL":"https:\/\/doi.org\/10.1007\/bf03190621","relation":{},"ISSN":["0378-7966","2107-0180"],"issn-type":[{"type":"print","value":"0378-7966"},{"type":"electronic","value":"2107-0180"}],"subject":[],"published":{"date-parts":[[2005,9]]}}}